Novartis AG (LON:0K9E)

Market Cap	170.50B
Revenue (ttm)	41.31B
Net Income (ttm)	9.54B
Shares Out	n/a
EPS (ttm)	4.69
PE Ratio	17.88
Forward PE	n/a
Dividend	2.47 (2.32%)
Ex-Dividend Date	Mar 12, 2025

Volume	59
Average Volume	12,837
Open	106.46
Previous Close	106.51
Day's Range	106.40 - 107.03
52-Week Range	92.39 - 120.72
Beta	n/a
RSI	67.69
Earnings Date	Jan 31, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.

Financial numbers in USD